Melvin D. Lobo
A5062435919- Blood Pressure and Hypertension Studies
- Heart Rate Variability and Autonomic Control
- Cardiovascular Syncope and Autonomic Disorders
- Hemodynamic Monitoring and Therapy
- Sodium Intake and Health
- Hormonal Regulation and Hypertension
- Cardiovascular Health and Disease Prevention
- Peripheral Artery Disease Management
- Renal and Vascular Pathologies
- Cerebrovascular and Carotid Artery Diseases
- Pharmacology and Obesity Treatment
- Migraine and Headache Studies
- Pharmaceutical industry and healthcare
- Venous Thromboembolism Diagnosis and Management
- Pharmaceutical Economics and Policy
- Vascular Procedures and Complications
- Cardiovascular Health and Risk Factors
- Pituitary Gland Disorders and Treatments
- Ultrasound and Hyperthermia Applications
- Central Venous Catheters and Hemodialysis
- Cardiac Health and Mental Health
- Adrenal Hormones and Disorders
- Cell Adhesion Molecules Research
- Protease and Inhibitor Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
William Harvey Research Institute
2015-2024
Queen Mary University of London
2015-2024
Barts Health NHS Trust
2013-2024
St Bartholomew's Hospital
2015-2023
National Institute for Health Research
2016-2022
Blood Cancer UK
2022
London Clinic
2022
National Health Service
2021
UCL Biomedical Research Centre
2020
New York Hospital Queens
2019
This ESH Position Paper 2021 with updated proposed recommendations was deemed necessary after the publication of a set new pivotal sham-controlled randomized clinical trials (RCTs), which provided important information about efficacy and safety endovascular device-based renal denervation (RDN) for hypertension treatment. RDN is effective in reducing or interrupting sympathetic signals to kidneys decreasing whole body activity. Five independent, fully completed, RCTs provide conclusive...
Importance Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and is resistant treatment. Objective To study the efficacy safety of without confounding influence antihypertensive medications hypertension. Design, Setting, Participants Sham-controlled, randomized clinical trial outcome assessors blinded treatment assignment was conducted between January 14, 2019, March 25, 2022, at 37...
Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). Establishing the magnitude and consistency of uRDN effect across HTN spectrum is clinically important.
Approximately 8–18% of all patients with high blood pressure (BP) are apparently resistant to drug treatment.1,2 In this situation, new strategies help reduce BP urgently needed but the complex pathophysiology hypertension makes search difficult. Not surprisingly in context, latest non-drug treatment which triggered controversy is catheter-based renal denervation (RDN).3,4 The method uses radiofrequency energy, or alternatively ultrasound chemical denervation, disrupt nerves within artery...
Animal and human data indicate pathological afferent signaling emanating from the carotid body that drives sympathetically mediated elevations in blood pressure conditions of hypertension. This first-in-man, proof-of-principle study tested safety feasibility unilateral resection 15 patients with drug-resistant The procedure proved to be safe feasible. Overall, no change was found. However, 8 showed significant reductions ambulatory coinciding decreases sympathetic activity. may a novel...
Background: The multicenter, international, randomized, blinded, sham-controlled RADIANCE-HTN SOLO trial (A Study of the ReCor Medical Paradise System in Clinical Hypertension) demonstrated a 6.3 mm Hg greater reduction daytime ambulatory systolic blood pressure (BP) at 2 months by endovascular ultrasound renal denervation (RDN) compared with sham procedure among patients not treated antihypertensive medications. We report 6-month results after addition recommended standardized stepped-care...
Abstract
Abstract Aims Catheter-based radiofrequency renal denervation (RF RDN) has recently been approved for clinical use in the European Society of Hypertension guidelines and by US Food Drug Administration. This study evaluated lifetime cost-effectiveness RF RDN using contemporary evidence. Methods results A decision–analytic model based on multivariate risk equations projected events, quality-adjusted life years (QALYs), costs. The consisted seven health states: hypertension alone, myocardial...
Importance Although early trials of endovascular renal denervation (RDN) for patients with resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was found to decrease blood pressure (BP) vs sham at 2 months in RHTN taking stable background medications the Study ReCor Medical Paradise System Clinical Hypertension (RADIANCE-HTN TRIO) trial. Objectives To report prespecified analysis persistence BP effects and safety uRDN 6 conjunction escalating antihypertensive...
BACKGROUND: The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, TRIO, and RADIANCE II Stage trials independently met their primary end point a greater reduction daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) patients with hypertension. To characterize longer-term effectiveness safety uRDN versus sham at 6 months, blinded addition antihypertensive treatments (AHTs), we...
The survival of endothelial cells is dependent on interactions between the matrix and integrins mediated through focal adhesions. Focal adhesion kinase (FAK) thought to play a key role in maintaining function cell survival, whereas caspase-mediated FAK proteolysis implicated disassembly during apoptosis. We examined relationship changes phosphorylation apoptosis primary porcine aortic (PAEC) induced by staurosporine, widely used apoptogenic agent diverse types. Staurosporine-induced PAEC was...
Objectives: The aim of this double-blind, randomized, sham-controlled study was to verify the blood pressure (BP)-lowering efficacy externally delivered focused ultrasound for renal denervation (RDN). Background: Nonrandomized, first proof-of-concept and experimental evidence suggested that noninvasive techniques RDN emerged as an alternative approach invasive technologies. Methods: WAVE IV, international, randomized (1 : 1) sham-controlled, double-blind prospective clinical study,...
<h3>Abstract</h3> Missense mutations in the <i>LRRK2</i> gene that lead to LRRK2 kinase hyperactivity can cause Parkinson's disease (PD). The link between and α-synuclein aggregation PD remains enigmatic. Numerous reports suggest critical functions microglial responses. Herein, we find LRRK2-positive immune cells brain represent CD68-positive pro-inflammatory, monocyte-derived macrophages, distinct from microglia. Rod fibrils stimulate activity enhanced recruitment of classical monocytes...
Creation of a central iliac arteriovenous anastomosis using novel nitinol coupler device results in an immediate, significant reduction blood pressure (BP). We present efficacy and safety findings at 12 months post-coupler insertion. This open-label, multicenter, prospective, randomized trial enrolled patients with baseline office systolic BP ≥140 mm Hg average daytime ambulatory ≥135/85 Hg. Subjects were randomly allocated to implantation continuing previous pharmacotherapy or maintain...
Nonadherence to medication is present in at least 50% of patients with apparent treatment-resistant hypertension. We examined the factors associated nonadherence as detected by a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based urine antihypertensive drug assay.All test results, carried out for uncontrolled hypertension (BP persistently >140/90 mmHg) between January 2015 and December 2016 single toxicology laboratory were analysed. Drugs compared drugs prescribed. Patients...